The last Qiagen takeover failed on shareholder math, not regulators: Thermo Fisher's 2020 offer lapsed when only 47.02% of shares were tendered against a 66.67% minimum. Thermo Fisher ($TMO) agreed on March 3, 2020 to pay €39 a share in cash, in a deal it valued at about $11.5 billion including roughly $1.4 billion of net debt. It raised the price to €43 on July 16, 2020, cut the acceptance threshold from 75%, and still came up short when the offer expired on August 10, 2020. Qiagen then paid Thermo a $95 million expense reimbursement. With Qiagen back in play in 2026 and $QGEN at $46.55 at the October 19, 2026 close, that episode is the best available script for how a new deal could work, and how it could break.
The Thermo Fisher bid for Qiagen, step by step
The 2020 deal had everything a merger trader wants on paper: a strategic buyer, a signed agreement, unanimous board support and a cash price. It still died.
| Date | Event |
|---|---|
| Mar 3, 2020 | Agreement signed: €39 a share in cash, about a 23% premium to Qiagen's March 2, 2020 closing price; minimum acceptance 75% |
| May 18, 2020 | Offer document published after approval by Germany's BaFin; acceptance period set to end July 27, 2020 |
| Jul 16, 2020 | Price raised to €43 (about a 35% premium to the same March 2 close); threshold cut to 66.67%; deadline moved to August 10; $95 million payable to Thermo if the threshold is missed |
| Aug 4, 2020 | Thermo confirms the August 10 expiry and says it will not launch another offer if this one fails |
| Aug 10, 2020 | Acceptance period ends with 107,546,187 shares tendered, 47.02% of the share capital |
| Aug 13, 2020 | Offer lapses, agreement terminated, $95 million expense reimbursement due to Thermo |
The original agreement, laid out in Thermo Fisher's March 2020 Form 8-K, also carried a $367 million termination fee payable by Qiagen in specified cases, such as accepting a rival offer, and a $575 million reverse fee payable by Thermo if antitrust approvals were not obtained by the long-stop date. Neither was the problem. The register was.
Why it failed: the holdout math
A 66.67% minimum means holders of just over one-third of the shares can sink a deal by doing nothing. In 2020 they did. Thermo Fisher's August 13, 2020 results announcement put acceptances at 47.02%, which leaves the offer 19.65 percentage points short of the lowered bar (arithmetic: 66.67 minus 47.02).
The loudest holdout was the hedge fund Davidson Kempner. MedTech Dive reported that it held about 3% of Qiagen when it first objected, argued the original offer "severely" undervalued the company, and raised its stake to 8% in early August, saying it would not tender under the revised terms. It put Qiagen's standalone fair value as high as €52 a share, about 21% above the €43 bid (arithmetic: 52 divided by 43, minus 1).
Timing did the rest. The deal was announced shortly before the World Health Organization declared COVID-19 a pandemic, and the pandemic led investors to reassess what Qiagen was worth. A 10.3% price bump (from €39 to €43) and a lower threshold were not enough to close that gap, even with every member of Qiagen's Supervisory and Managing Boards tendering their own shares.
The lesson: in a Qiagen tender, the board's recommendation opens the door, but a supermajority of the shareholder register has to walk through it.
How a Qiagen takeover would pay NYSE shareholders
Qiagen is a Dutch N.V. whose US listing is on the NYSE, so a bid has to satisfy several rulebooks at once. Any new deal could be structured differently, but the 2020 filings show the template.
- The offer: a public tender offer for all shares, run under the German Securities Acquisition and Takeover Act, with the offer document approved by BaFin, the Dutch Decree on Public Takeovers also applying, and a tender offer statement filed with the SEC. US holders received an offer to purchase and letter of transmittal, with D.F. King acting as US information agent.
- The clock: an initial acceptance period of ten weeks, which could be extended; a further two-week acceptance period under German law once all conditions other than antitrust were met; and up to twelve months after expiry for antitrust clearances.
- The conditions: the minimum acceptance threshold and regulatory approvals.
- The back end: a top-up option letting the buyer subscribe for new shares at the offer price to reach 80% plus one share, then a post-offer restructuring, either a merger into a buyer subsidiary or an asset sale, followed by liquidation. Holders who did not tender would receive cash equal to the offer price. Qiagen would be delisted from the NYSE. At 95% ownership, the buyer could also squeeze out the rest at a price set by the Amsterdam Enterprise Chamber.
Two practical points for US holders. First, the 2020 price was set in euros, so its value in US$ moved with the exchange rate through the offer period. Second, tendering and being cashed out in a back-end liquidation can carry different tax consequences; this is not tax advice, so check with a tax adviser.
What 2020 teaches Qiagen traders in 2026
| Item | 2020 Thermo Fisher deal | 2026 situation |
|---|---|---|
| Status | Signed agreement, March 3, 2020 | No bid announced as of Oct 19, 2026 |
| Price | €39, raised to €43 | Bloomberg reported Jul 9, 2026 that some suitors may consider at least $50 |
| Named buyers | Thermo Fisher | Reports name EQT, Advent, KKR, TPG, Bain Capital; none confirmed |
| Threshold | 75%, cut to 66.67% | Unknown until a bid is made |
| Outcome | 47.02% tendered; lapsed; $95 million to Thermo | Qiagen confirms a strategic review with advisers |
The threshold is the deal. If a 2026 offer arrives, the minimum acceptance level, and whether the buyer can lower it, deserves as much attention as the headline price.
Bumps help, but they are not a guarantee. Thermo raised its price and lowered its bar and still missed by almost 20 points.
Know the walk-away cost. The 2020 failure cost Qiagen $95 million in cash. Break-fee terms in any new agreement show how committed each side is.
The register has a memory. Shareholders rejected €43 once. In August 2026, Qiagen said its Supervisory Board continues to evaluate opportunities to create value compared with its standalone plan, which is the bar any buyer now has to clear. The only reported price figure, $50, sits 7.4% above the $46.55 October 19, 2026 close. For the full 2026 report timeline and the premium math, see our explainer on the current Qiagen takeover talks, and our initial coverage of the October 2 advanced-talks report. For another live rumor in a different sector, see Arm's reported interest in Eliyan, and find more deal analysis in the Analysis section.
Bull/Bear Verdict
Bull Case: 2020 proved Qiagen holders can force a buyer to pay up, as Thermo lifted its offer from €39 to €43, and the $50 figure reported in July 2026 sits 7.4% above the $46.55 October 19, 2026 close.
Bear Case: Even a signed, board-backed cash deal at a 35% premium collapsed in 2020, and in 2026 there is no signed deal at all, only reports, while $QGEN trades 10.7% above its October 1, 2026 close.
FAQ
Why did Thermo Fisher's takeover of Qiagen fail?
Only 47.02% of Qiagen's shares were tendered by August 10, 2020, short of the 66.67% minimum acceptance threshold, so the offer lapsed. Holdouts, led publicly by Davidson Kempner, argued the €43 price undervalued Qiagen.
How much did Thermo Fisher offer for Qiagen?
€39 a share in cash at signing on March 3, 2020, which Thermo valued at about $11.5 billion including about $1.4 billion of net debt. The price was raised to €43 a share on July 16, 2020.
What happens to NYSE shareholders who don't tender in a Qiagen takeover?
Under the 2020 structure, a successful buyer could run a post-offer restructuring and liquidation that pays non-tendering holders cash equal to the offer price, then delist the shares, or squeeze them out at 95% ownership. A new deal could use different terms.
Is Thermo Fisher bidding for Qiagen again?
None of the 2026 reports on the talks names Thermo Fisher. In August 2020 Thermo said it would not launch another offer if that offer failed.